Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Cell Line Models of Molecular Subtypes of Colorectal Cancer.

Mooi JK, Luk IY, Mariadason JM.

Methods Mol Biol. 2018;1765:3-26. doi: 10.1007/978-1-4939-7765-9_1.

PMID:
29589298
2.

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.

Lau DK, Tay RY, Yeung YH, Chionh F, Mooi J, Murone C, Skrinos E, Price TJ, Mariadason JM, Tebbutt NC.

Br J Cancer. 2018 Apr;118(7):966-971. doi: 10.1038/s41416-018-0021-1. Epub 2018 Mar 12.

PMID:
29527009
3.

Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ-Dependent Manner.

Eissmann MF, Dijkstra C, Wouters MA, Baloyan D, Mouradov D, Nguyen PM, Davalos-Salas M, Putoczki TL, Sieber OM, Mariadason JM, Ernst M, Masson F.

Cancer Immunol Res. 2018 Apr;6(4):409-421. doi: 10.1158/2326-6066.CIR-17-0218. Epub 2018 Feb 20.

PMID:
29463593
4.

DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.

Tögel L, Nightingale R, Wu R, Chüeh AC, Al-Obaidi S, Luk I, Dávalos-Salas M, Chionh F, Murone C, Buchanan DD, Chatterton Z, Sieber OM, Arango D, Tebbutt NC, Williams D, Dhillon AS, Mariadason JM.

Sci Rep. 2018 Jan 29;8(1):1767. doi: 10.1038/s41598-018-20176-9.

5.

Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer.

Dopeso H, Rodrigues P, Bilic J, Bazzocco S, Cartón-García F, Macaya I, de Marcondes PG, Anguita E, Masanas M, Jiménez-Flores LM, Martínez-Barriocanal Á, Nieto R, Segura MF, Schwartz S Jr, Mariadason JM, Arango D.

Br J Cancer. 2018 Jan;118(1):106-116. doi: 10.1038/bjc.2017.420. Epub 2017 Dec 5.

PMID:
29206819
6.

Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer.

Chüeh AC, Liew MS, Russell PA, Walkiewicz M, Jayachandran A, Starmans MHW, Boutros PC, Wright G, Barnett SA, Mariadason JM, John T.

Oncotarget. 2017 May 23;8(43):74036-74048. doi: 10.18632/oncotarget.18198. eCollection 2017 Sep 26.

7.

Aberrant DNA Methylation in Colorectal Cancer: What Should We Target?

Tse JWT, Jenkins LJ, Chionh F, Mariadason JM.

Trends Cancer. 2017 Oct;3(10):698-712. doi: 10.1016/j.trecan.2017.08.003. Epub 2017 Sep 12. Review.

PMID:
28958388
8.

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.

Tutuka CSA, Andrews MC, Mariadason JM, Ioannidis P, Hudson C, Cebon J, Behren A.

Mol Cancer. 2017 Jun 28;16(1):112. doi: 10.1186/s12943-017-0684-x.

9.

Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.

Wang J, Mouradov D, Wang X, Jorissen RN, Chambers MC, Zimmerman LJ, Vasaikar S, Love CG, Li S, Lowes K, Leuchowius KJ, Jousset H, Weinstock J, Yau C, Mariadason J, Shi Z, Ban Y, Chen X, Coffey RJC, Slebos RJC, Burgess AW, Liebler DC, Zhang B, Sieber OM.

Gastroenterology. 2017 Oct;153(4):1082-1095. doi: 10.1053/j.gastro.2017.06.008. Epub 2017 Jun 16.

PMID:
28625833
10.

ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types.

Chüeh AC, Tse JWT, Dickinson M, Ioannidis P, Jenkins L, Togel L, Tan B, Luk I, Davalos-Salas M, Nightingale R, Thompson MR, Williams BRG, Lessene G, Lee EF, Fairlie WD, Dhillon AS, Mariadason JM.

Clin Cancer Res. 2017 Sep 15;23(18):5573-5584. doi: 10.1158/1078-0432.CCR-17-0466. Epub 2017 Jun 13.

PMID:
28611196
11.

K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.

Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM.

Mol Oncol. 2017 Sep;11(9):1130-1142. doi: 10.1002/1878-0261.12078. Epub 2017 Jun 14.

12.

Loss of the EPH receptor B6 contributes to colorectal cancer metastasis.

Mateo-Lozano S, Bazzocco S, Rodrigues P, Mazzolini R, Andretta E, Dopeso H, Fernández Y, Del Llano E, Bilic J, Suárez-López L, Macaya I, Cartón-García F, Nieto R, Jimenez-Flores LM, de Marcondes PG, Nuñez Y, Afonso E, Cacci K, Hernández-Losa J, Landolfi S, Abasolo I, Ramón Y Cajal S, Mariadason JM, Schwartz S Jr, Matsui T, Arango D.

Sci Rep. 2017 Mar 6;7:43702. doi: 10.1038/srep43702.

13.

Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.

Tögel L, Nightingale R, Chueh AC, Jayachandran A, Tran H, Phesse T, Wu R, Sieber OM, Arango D, Dhillon AS, Dawson MA, Diez-Dacal B, Gahman TC, Filippakopoulos P, Shiau AK, Mariadason JM.

Mol Cancer Ther. 2016 Jun;15(6):1217-26. doi: 10.1158/1535-7163.MCT-15-0724. Epub 2016 Mar 16.

14.

By moonlighting in the nucleus, villin regulates epithelial plasticity.

Patnaik S, George SP, Pham E, Roy S, Singh K, Mariadason JM, Khurana S.

Mol Biol Cell. 2016 Feb 1;27(3):535-48. doi: 10.1091/mbc.E15-06-0453. Epub 2015 Dec 10.

15.

Colorectal cancer atlas: An integrative resource for genomic and proteomic annotations from colorectal cancer cell lines and tissues.

Chisanga D, Keerthikumar S, Pathan M, Ariyaratne D, Kalra H, Boukouris S, Mathew NA, Al Saffar H, Gangoda L, Ang CS, Sieber OM, Mariadason JM, Dasgupta R, Chilamkurti N, Mathivanan S.

Nucleic Acids Res. 2016 Jan 4;44(D1):D969-74. doi: 10.1093/nar/gkv1097. Epub 2015 Oct 22.

16.

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.

Weickhardt AJ, Williams DS, Lee CK, Chionh F, Simes J, Murone C, Wilson K, Parry MM, Asadi K, Scott AM, Punt CJ, Nagtegaal ID, Price TJ, Mariadason JM, Tebbutt NC.

Br J Cancer. 2015 Jun 30;113(1):37-45.

17.

The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner.

Shin J, Carr A, Corner GA, Tögel L, Dávalos-Salas M, Tran H, Chueh AC, Al-Obaidi S, Chionh F, Ahmed N, Buchanan DD, Young JP, Malo MS, Hodin RA, Arango D, Sieber OM, Augenlicht LH, Dhillon AS, Weber TK, Mariadason JM.

J Biol Chem. 2015 Jun 19;290(25):15392. doi: 10.1074/jbc.A114.557546. No abstract available.

18.

Highly Expressed Genes in Rapidly Proliferating Tumor Cells as New Targets for Colorectal Cancer Treatment.

Bazzocco S, Dopeso H, Carton-Garcia F, Macaya I, Andretta E, Chionh F, Rodrigues P, Garrido M, Alazzouzi H, Nieto R, Sanchez A, Schwartz S Jr, Bilic J, Mariadason JM, Arango D.

Clin Cancer Res. 2015 Aug 15;21(16):3695-704. doi: 10.1158/1078-0432.CCR-14-2457. Epub 2015 May 5.

19.

FunRich: An open access standalone functional enrichment and interaction network analysis tool.

Pathan M, Keerthikumar S, Ang CS, Gangoda L, Quek CY, Williamson NA, Mouradov D, Sieber OM, Simpson RJ, Salim A, Bacic A, Hill AF, Stroud DA, Ryan MT, Agbinya JI, Mariadason JM, Burgess AW, Mathivanan S.

Proteomics. 2015 Aug;15(15):2597-601. doi: 10.1002/pmic.201400515. Epub 2015 Jun 17.

PMID:
25921073
20.

PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity.

Gilan O, Diesch J, Amalia M, Jastrzebski K, Chueh AC, Verrills NM, Pearson RB, Mariadason JM, Tulchinsky E, Hannan RD, Dhillon AS.

Oncogene. 2015 Mar 5;34(10):1340. doi: 10.1038/onc.2014.460. No abstract available.

PMID:
25740609
21.

Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer.

Pereira L, Mariadason JM, Hannan RD, Dhillon AS.

Front Oncol. 2015 Feb 2;5:13. doi: 10.3389/fonc.2015.00013. eCollection 2015. Review.

22.

RHOA inactivation enhances Wnt signalling and promotes colorectal cancer.

Rodrigues P, Macaya I, Bazzocco S, Mazzolini R, Andretta E, Dopeso H, Mateo-Lozano S, Bilić J, Cartón-García F, Nieto R, Suárez-López L, Afonso E, Landolfi S, Hernandez-Losa J, Kobayashi K, Ramón y Cajal S, Tabernero J, Tebbutt NC, Mariadason JM, Schwartz S Jr, Arango D.

Nat Commun. 2014 Nov 21;5:5458. doi: 10.1038/ncomms6458.

23.

Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer.

Augustine TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, Aparo S, Maitra R, Goel S.

Br J Cancer. 2015 Jan 20;112(2):313-8. doi: 10.1038/bjc.2014.561. Epub 2014 Nov 20.

24.

Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy.

Donnard E, Asprino PF, Correa BR, Bettoni F, Koyama FC, Navarro FC, Perez RO, Mariadason J, Sieber OM, Strausberg RL, Simpson AJ, Jardim DL, Reis LF, Parmigiani RB, Galante PA, Camargo AA.

Oncotarget. 2014 Oct 15;5(19):9199-213.

25.

The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner.

Shin J, Carr A, Corner GA, Tögel L, Dávalos-Salas M, Tran H, Chueh AC, Al-Obaidi S, Chionh F, Ahmed N, Buchanan DD, Young JP, Malo MS, Hodin RA, Arango D, Sieber OM, Augenlicht LH, Dhillon AS, Weber TK, Mariadason JM.

J Biol Chem. 2014 Sep 5;289(36):25306-16. doi: 10.1074/jbc.M114.557546. Epub 2014 Jul 18. Erratum in: J Biol Chem. 2015 Jun 19;290(25):15392. Dávaos-Salas, Mercedes [Corrected to Dávalos-Salas, Mercedes].

26.

Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.

Maitra R, Seetharam R, Tesfa L, Augustine TA, Klampfer L, Coffey MC, Mariadason JM, Goel S.

Oncotarget. 2014 May 15;5(9):2807-19.

27.

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, Arango D, Strausberg RL, Buchanan D, Wormald S, O'Connor L, Wilding JL, Bicknell D, Tomlinson IP, Bodmer WF, Mariadason JM, Sieber OM.

Cancer Res. 2014 Jun 15;74(12):3238-47. doi: 10.1158/0008-5472.CAN-14-0013. Epub 2014 Apr 22.

28.

Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells.

Diesch J, Sanij E, Gilan O, Love C, Tran H, Fleming NI, Ellul J, Amalia M, Haviv I, Pearson RB, Tulchinsky E, Mariadason JM, Sieber OM, Hannan RD, Dhillon AS.

PLoS One. 2014 Mar 21;9(3):e88950. doi: 10.1371/journal.pone.0088950. eCollection 2014.

29.

PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity.

Gilan O, Diesch J, Amalia M, Jastrzebski K, Chueh AC, Verrills NM, Pearson RB, Mariadason JM, Tulchinsky E, Hannan RD, Dhillon AS.

Oncogene. 2015 Mar 5;34(10):1333-9. doi: 10.1038/onc.2014.26. Epub 2014 Mar 17. Erratum in: Oncogene. 2015 Mar 5;34(10):1340.

PMID:
24632621
30.

Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.

Ung N, Putoczki TL, Stylli SS, Ng I, Mariadason JM, Chan TA, Zhu HJ, Luwor RB.

Cancer Biol Ther. 2014 May;15(5):623-32. doi: 10.4161/cbt.28179. Epub 2014 Feb 20.

31.

Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells.

Chueh AC, Tse JW, Tögel L, Mariadason JM.

Antioxid Redox Signal. 2015 Jul 1;23(1):66-84. doi: 10.1089/ars.2014.5863. Epub 2014 Mar 27. Review.

32.

FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.

Tan B, Anaka M, Deb S, Freyer C, Ebert LM, Chueh AC, Al-Obaidi S, Behren A, Jayachandran A, Cebon J, Chen W, Mariadason JM.

Oncotarget. 2014 Jan 15;5(1):264-76.

33.

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

Aisner DL, Nguyen TT, Paskulin DD, Le AT, Haney J, Schulte N, Chionh F, Hardingham J, Mariadason J, Tebbutt N, Doebele RC, Weickhardt AJ, Varella-Garcia M.

Mol Cancer Res. 2014 Jan;12(1):111-8. doi: 10.1158/1541-7786.MCR-13-0479-T. Epub 2013 Dec 2.

34.

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

Andrews MC, Behren A, Chionh F, Mariadason J, Vella LJ, Do H, Dobrovic A, Tebbutt N, Cebon J.

J Clin Oncol. 2013 Dec 10;31(35):e448-51. doi: 10.1200/JCO.2013.50.4118. Epub 2013 Nov 4. No abstract available.

PMID:
24190114
35.

Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008.

Burvenich IJ, Lee FT, Cartwright GA, O'Keefe GJ, Makris D, Cao D, Gong S, Chueh AC, Mariadason JM, Brechbiel MW, Beckman RA, Fujiwara K, von Roemeling R, Scott AM.

Clin Cancer Res. 2013 Nov 1;19(21):5984-93. doi: 10.1158/1078-0432.CCR-12-3104. Epub 2013 Sep 17.

36.

Carcinoma of the colon in an adult with intestinal malrotation.

Donaire M, Mariadason J, Stephens D, Pillarisetty S, Wallack MK.

Case Rep Surg. 2013;2013:525081. doi: 10.1155/2013/525081. Epub 2013 Jul 29.

37.

Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts.

Lee ST, Ji H, Greening DW, Speirs RW, Rigopoulos A, Pillay V, Murone C, Vitali A, Stühler K, Johns TG, Corner GA, Mariadason JM, Simpson RJ, Scott AM.

Growth Factors. 2013 Oct;31(5):154-64. doi: 10.3109/08977194.2013.824435. Epub 2013 Aug 20.

PMID:
23957735
38.

Role of the faecolith in modern-day appendicitis.

Singh JP, Mariadason JG.

Ann R Coll Surg Engl. 2013 Jan;95(1):48-51. doi: 10.1308/003588413X13511609954851.

39.

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S.

Clin Cancer Res. 2013 Feb 1;19(3):657-67. doi: 10.1158/1078-0432.CCR-11-1446. Epub 2012 Dec 18.

40.

SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.

Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, Day F, Li S, Tsui C, Lipton L, Desai J, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Zhu HJ, Mariadason JM, Burgess AW, Busam D, Zhao Q, Strausberg RL, Gibbs P, Sieber OM.

Cancer Res. 2013 Jan 15;73(2):725-35. doi: 10.1158/0008-5472.CAN-12-2706. Epub 2012 Nov 8.

41.

β-catenin negatively regulates expression of the prostaglandin transporter PGT in the normal intestinal epithelium and colorectal tumour cells: a role in the chemopreventive efficacy of aspirin?

Smartt HJ, Greenhough A, Ordóñez-Morán P, Al-Kharusi M, Collard TJ, Mariadason JM, Huelsken J, Williams AC, Paraskeva C.

Br J Cancer. 2012 Oct 23;107(9):1514-7. doi: 10.1038/bjc.2012.430. Epub 2012 Oct 2.

42.

Brush border myosin Ia inactivation in gastric but not endometrial tumors.

Mazzolini R, Rodrigues P, Bazzocco S, Dopeso H, Ferreira AM, Mateo-Lozano S, Andretta E, Woerner SM, Alazzouzi H, Landolfi S, Hernandez-Losa J, Macaya I, Suzuki H, Ramón y Cajal S, Mooseker MS, Mariadason JM, Gebert J, Hofstra RM, Reventós J, Yamamoto H, Schwartz S Jr, Arango D.

Int J Cancer. 2013 Apr 15;132(8):1790-9. doi: 10.1002/ijc.27856. Epub 2012 Oct 20.

43.

Negative appendicectomy rate as a quality metric in the management of appendicitis: impact of computed tomography, Alvarado score and the definition of negative appendicectomy.

Mariadason JG, Wang WN, Wallack MK, Belmonte A, Matari H.

Ann R Coll Surg Engl. 2012 Sep;94(6):395-401. doi: 10.1308/003588412X13171221592131.

44.

Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer.

Haigentz M Jr, Kim M, Sarta C, Lin J, Keresztes RS, Culliney B, Gaba AG, Smith RV, Shapiro GI, Chirieac LR, Mariadason JM, Belbin TJ, Greally JM, Wright JJ, Haddad RI.

Oral Oncol. 2012 Dec;48(12):1281-8. doi: 10.1016/j.oraloncology.2012.05.024. Epub 2012 Jun 28.

45.

Therapeutic targeting of the epidermal growth factor receptor in human cancer.

Dhomen NS, Mariadason J, Tebbutt N, Scott AM.

Crit Rev Oncog. 2012;17(1):31-50. Review.

PMID:
22471663
46.

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.

Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC.

J Clin Oncol. 2012 May 1;30(13):1505-12. doi: 10.1200/JCO.2011.38.6599. Epub 2012 Mar 12.

PMID:
22412142
47.

FOXP3 is not mutated in human melanoma.

Tan B, Behren A, Anaka M, Vella L, Cebon J, Mariadason JM, Chen W.

Pigment Cell Melanoma Res. 2012 May;25(3):398-400. doi: 10.1111/j.1755-148X.2012.00993.x. Epub 2012 Mar 16. No abstract available.

PMID:
22372921
48.

Villin expression is frequently lost in poorly differentiated colon cancer.

Arango D, Al-Obaidi S, Williams DS, Dopeso H, Mazzolini R, Corner G, Byun DS, Carr AA, Murone C, Tögel L, Zeps N, Aaltonen LA, Iacopetta B, Mariadason JM.

Am J Pathol. 2012 Apr;180(4):1509-21. doi: 10.1016/j.ajpath.2012.01.006. Epub 2012 Feb 18.

49.

Brush border myosin Ia has tumor suppressor activity in the intestine.

Mazzolini R, Dopeso H, Mateo-Lozano S, Chang W, Rodrigues P, Bazzocco S, Alazzouzi H, Landolfi S, Hernández-Losa J, Andretta E, Alhopuro P, Espín E, Armengol M, Tabernero J, Ramón y Cajal S, Kloor M, Gebert J, Mariadason JM, Schwartz S Jr, Aaltonen LA, Mooseker MS, Arango D.

Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1530-5. doi: 10.1073/pnas.1108411109. Epub 2012 Jan 18.

50.

PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, Rajdev L, Mariadason JM, Tanaka K, Goel S.

Clin Colorectal Cancer. 2012 Jun;11(2):143-50. doi: 10.1016/j.clcc.2011.12.001. Epub 2012 Jan 28.

Supplemental Content

Loading ...
Support Center